Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

NCT02120456 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

224

Enrollment

INDUSTRY

Sponsor class

Conditions

Actinic Keratosis

Interventions

DRUG: LEO 43204
DRUG: Placebo

Sponsor

LEO Pharma